Introduction: Celecoxib, a selective COX-2 inhibitor, presents a promising avenue for pain relief; however, concerns have been raised regarding its increased risk of cardiovascular events, leading to a black box warning. Additionally, the therapeutic potential of celecoxib is hindered by its unfavorable physicochemical properties and associated adverse effects. This review aims to explore new formulations of celecoxib for safe and effective pain management. Methods: The present work was conducted based on a literature search of selected relevant articles from indexed databases like Science Direct, PubMed and google scholar by using key words like “celecoxib”, “new formulations”, and “pain management”, and related combinations. Results: Recent endeavors have been directed towards the development of modern dosage forms of celecoxib e.g., self-micro emulsifying drug delivery systems (SMEDDS), micelles, lipid-silica hybrid, nanostructured lipid carriers (NLCs). These innovative approaches aim to improve oral bioavailability, thereby minimizing doses, as well as to create long-acting injectables for non-systemic administration, and devise topical delivery systems. Conclusion: By embracing these advancements in technology and formulation, it is plausible to mitigate the risks associated with celecoxib. However, further clinical studies are imperative to refine these formulations and optimize celecoxib’s utility in pain management, while concurrently ensuring efficacy and safety.
Thapa et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: